Skip to content

Efficacy and Safety Study of Feminine Hygiene Wash

A Randomized, Double-blinded, Comparative Clinical Study to Evaluate the Efficacy and Safety of Feminine hygiene wash of Cavinkare - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080847
Enrollment
54
Registered
2025-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N908- Other specified noninflammatory disorders of vulva and perineum

Interventions

Intervention1: Feminine Hygiene Wash of Cavinkare: Composition: 1.Water 52.98-64.75 2.Cocamidopropyl betane 18.00-22.00 3.Coco glucoside 9.00-11.00 4.Glycerin 2.70-3.30 5.Lauryl glucoside 1.80-2.20 6.

Sponsors

Cavinkare, India.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Proper written informed consent obtained from the patient before any procedure performed. 2. Healthy females with perineal discomfort between the age group of 18-65 years. 3. Subjects not have participated in any other clinical trial during the past 3 months

Exclusion criteria

Exclusion criteria: 1. Female Subjects with sexually transmittable diseases and immune-compromised state & menstrual irregularities. 2. Pregnant or lactating women 3. Subjects with known history of vaginal candidal infections. 4. Hypersensitivity to any of the components of the test or reference formulation. 5. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in this clinical study.

Design outcomes

Primary

MeasureTime frame
1. An assessment for vulval pH and degree of pruritus,burning, vulvo vaginal erythema and oedema, dryness and dyspareunia 2. Vulval swabs will be taken before administering the test product for bacterial and fungal culture. Swabs will also be taken at the end of the study 3. self-assessment scoring by the subject on subject’s overall condition 4. Quality of life will also be assessed using SF 12 questionnaireTimepoint: Baseline and at 2 weeks

Secondary

MeasureTime frame
To monitor for any adverse events during the study periodTimepoint: Baseline to 2 weeks

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

SRM Medical College Hospital and Research Centre

anuradhm@srmist.edu.in9042038136

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026